Zurzuvae Capsule
Product Images NDC 64406-030

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Zurzuvae (NDC 64406-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biogen Ma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zur00 0011 01)

Chemical structure of zuranolone, the active ingredient in ZURZUVAE capsules. The diagram shows the molecular framework with rings and functional groups clearly depicted.*

FDA Label Image

Figure 1 (Zur00 0011 02)

A pharmacokinetic chart showing the geometric mean ratios (GMR) and 90% confidence intervals (CI) for Cmax and AUC parameters across different populations including age groups (>=65 years), sexes (female), and varying degrees of hepatic and renal impairment (mild, moderate, severe). The chart compares changes relative to a reference group with numerical GMR values provided alongside each comparison.*

FDA Label Image

Figure 2 (Zur00 0011 03)

A forest plot showing the pharmacokinetic (PK) effects on Cmax and AUC parameters with 90% confidence intervals for various interacting compounds including the Cytochrome P450 3A inducer rifampin, Cytochrome P450 3A inhibitor itraconazole, and CNS active agents alprazolam and ethanol. The horizontal axis represents the change relative to reference values on a logarithmic scale from 0.1 to 2.0.*

FDA Label Image

Figure 3 (Zur00 0011 04)

Line graph comparing the Least Squares mean change from baseline (HAM-D total score) over 45 days between placebo and ZURZUVAE 50 mg. The x-axis represents time in days, with treatment phases labeled 'On drug' and 'Off drug'. The y-axis shows change from baseline, with ZURZUVAE demonstrating a greater decrease in HAM-D score than placebo throughout the study period.*

FDA Label Image

Principal Display Panel (ZURZUVAE 25mg Carton Label)

Carton packaging label for ZURZUVAE 25 mg capsules containing zuranolone. The label shows the dosage strength as 25 mg, specifies oral use, and includes a note to dispense with the accompanying Medication Guide. The package contains 14 capsules. It is manufactured for Biogen Inc., Cambridge, MA. Storage instructions and dosage warnings are also noted on the carton.*

FDA Label Image

Principal Display Panel (ZURZUVAE 25mg Blister Carton Label)

Packaging label for ZURZUVAE 25 mg capsules containing zuranolone. This prescription oral capsule package includes a 14-day blister pack with 28 capsules total. The label indicates a 50 mg daily dose and states the product is manufactured for Biogen Inc. in Cambridge, MA. Storage instructions and a medication guide notice are also shown.*

FDA Label Image

Principal Display Panel (30 mg Bottle Carton)

Packaging label for ZURZUVAE 30 mg capsules containing zuranolone. The label designates the drug as for oral use and includes a caution to dispense with an accompanying medication guide. The package holds 14 capsules. It is manufactured for Biogen Inc., Cambridge, MA, and lists storage instructions at room temperature. The label also features trademarks and barcodes.*

FDA Label Image

Principal Display Panel (20 mg Bottle Carton)

The packaging label for ZURZUVAE 20 mg capsules (zuranolone) displays dosage strength prominently in yellow highlight. It states oral use and instructs dispensing with the accompanying Medication Guide. The label shows the quantity as 14 capsules, manufacturer details Biogen Inc., and storage instructions. The design includes the proprietary name, generic name, IV classification, and barcode symbols on a white and yellow background.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.